



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 1 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001

GROUP: 1644

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	07/348,237	5/5/89	Rosenblum et al.			
	A2	4,196,265	4/1/80	Koprowski et al.			
	A3	4,469,797	9/4/84	Albarella			
	A4	4,676,980	6/30/87	Segal et al.			
	A5	4,816,567	3/28/89	Cabilly et al.			
	A6	4,946,778	8/7/90	Ladner et al.			
	A7	5,019,368	5/28/91	Epstein et al.			
	A8	5,073,627	12/17/91	Curtis et al.			
	A9	5,114,711	5/19/92	Bell et al.			
	A10	5,116,964	5/26/92	Capon et al.			
	A11	5,199,942	4/6/93	Gillis			
	A12	5,225,538	7/6/93	Capon et al.			
	A13	5,225,539	7/6/93	Winter			
	A14	5,258,498	11/2/93	Huston et al.			
	A15	5,314,995	5/24/94	Fell, Jr. et al.			
	A16	5,349,053	9/20/94	Landolfi			
	A17	5,359,035	10/25/94	Habermann			
	A18	5,514,582	5/7/96	Capon et al.			
	A19	5,538,866	7/23/96	Israeli et al.			
	A20	5,541,087	7/30/96	Lo et al.			
	A21	5,543,297	8/6/96	Cromlish, et al.			
	A22	5,552,524	09/03/96	Basinski et al.			
	A23	5,585,089	12/17/96	Queen et al.			
	A24	5,609,846	3/11/97	Goldenberg			
	A25	5,624,821	4/29/97	Winter et al.			

EXAMINER David A. Saunders

DATE CONSIDERED

3/1/04

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900des  
7/5/05

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

<i>all</i>	A26	5,639,725	6/17/97	O'Reilly et al.	—	✓	
	A27	5,645,835	7/8/97	Fell, Jr. et al.	—	✓	
	A28	5,650,492	7/22/97	Gately et al.	—	✓	
	A29	5,667,776	9/16/97	Zimmerman et al.	—	✓	
	A30	5,679,543	10/21/97	Lawlis	—	✓	
	A31	5,691,309	11/25/97	Basinski et al.	—	✓	
	A32	5,709,859	1/20/98	Aruffo et al.	—	✓	
	A33	5,719,266	02/17/98	DiMarchi et al.	—	✓	
	A34	5,726,044	3/10/98	Lo et al.	—	✓	
	A35	5,728,552	3/17/98	Fujisawa et al.	—	✓	
	A36	5,733,876	3/31/98	O'Reilly et al.	—	✓	
	A37	5,756,461	05/26/98	Stephens	—	✓	
	A38	5,759,551	6/2/98	Ladd et al.	—	✓	
	A39	5,770,195	6/23/98	Hudziak et al.	—	✓	
	A40	5,800,810	9/1/98	Doyle et al.	—	✓	
	A41	5,807,715	9/15/98	Morrison et al.	—	✓	
	A42	5,827,516	10/27/98	Urban et al.	—	✓	
	A43	5,837,682	11/17/98	Folkman et al.	—	✓	
	A44	5,843,423	12/1/98	Lyman et al.	—	✓	
	A45	5,854,205	12/29/98	O'Reilly et al.	—	✓	
	A46	5,856,298	1/5/99	Strickland	—	✓	
	A47	5,858,347	1/12/99	Bauer et al.	—	✓	
	A48	5,885,795	3/23/99	O'Reilly et al.	—	✓	
	A49	5,886,178	3/23/99	Allen et al.	—	✓	
	A50	5,888,772	3/30/99	Okasinski et al.	—	✓	
	A51	5,922,685	7/13/99	Rakhmilevich et al.	—	✓	
	A52	5,994,126	11/30/99	Steinman et al.	—	✓	
✓	A53	6,080,409	6/27/00	Laus et al.	—	✓	

**RECEIVED**

NOV 1 0-2803

TECH CENTER 1600/2200

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*3/1/04*



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 3 OF 16

FORM PTO - 1449	ATTORNEY DOCKET NO.: LEX-011 (4006/23)
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	APPLICANT(S): Gillies et al.
	SERIAL NO.: 09/780,668      CONF.: 8264
	FILING DATE: February 09, 2001      GROUP: 1644

<i>gnt</i>	A54	6,086,875	7/11/00	Blumberg et al.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	A55	6,169,070	1/2/01	Chen et al.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	A56	6,171,588	1/9/01	Carron et al.	<input type="checkbox"/>	<input type="checkbox"/>	
	A57	6,277,375	8/21/01	Ward	<input type="checkbox"/>	<input type="checkbox"/>	
	A58	6,348,192	2/19/02	Chan et al.	<input type="checkbox"/>	<input type="checkbox"/>	
	A59	6,406,689	6/18/02	Falkenberg et al.	<input type="checkbox"/>	<input type="checkbox"/>	

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>gnt</i>	B1	0 158 198 A1	10/16/85	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B2	0 211 769 A2	2/25/87	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B3	0 256 714 A2	2/24/88	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B4	0 294 703 A2	12/14/88	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B5	0 308 936 B1	3/29/89	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B6	0 314 317 B1	5/3/89	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B7	0 318 554 B1	6/7/89	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B8	0 319 012 A2	6/7/89	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B9	0 326 120 B1	8/2/89	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B10	0 350 230 A2	1/10/90	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B11	0 375 562 B1	6/27/90	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B12	0 396 387 A2	11/7/90	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B13	0 439 095 A2	7/31/91	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B14	0 511 747 A1	11/4/92	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B15	0 601 043 B1	6/15/94	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B16	0 640 619 A1	3/1/95	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B17	0 668 353 A1	8/23/95	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
	B18	0 706 799 A2	4/17/96	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y
<i>VI</i>	B19	0 790 309 A1	8/20/97	EP	<input type="checkbox"/>	<input type="checkbox"/>			Y

RECEIVED  
NOV 1 4 2003  
TECH CENTER 1600/2900

EXAMINER

*Daniel A. Saunders*

DATE CONSIDERED

*3/1/04*

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

<i>sub</i>	B20	21725/88	3/23/89	AU	—	—		Y
	<del>B21</del>	<del>931001153</del>	<del>7/14/93</del>	<del>CN</del>	—	—		<del>N</del>
<i>sub</i>	B22	931001153	7/14/93	CN	—	—	Y	Y
	<del>B23</del>	<del>37 12985 A1</del>	<del>11/9/88</del>	<del>DE</del>	—	—		<del>N</del>
<i>sub</i>	B24	37 12985	11/2/88	DE	—	—	Y	Y
<i>sub</i>	B25	2 292 382 A	2/21/96	GB	—	—		Y
	<del>B26</del>	<del>63-267278</del>	<del>11/4/88</del>	<del>JP</del>	—	—		<del>N</del>
<i>sub</i>	B27	63-267278	11/4/88	JP	—	—	Y	Y
	<del>B28</del>	<del>63-267296</del>	<del>11/4/88</del>	<del>JP</del>	—	—		<del>N</del>
<i>sub</i>	B29	63-267296	11/4/88	JP	—	—	Y	Y
	B30	0 237 019 A2	9/16/87	EP	—	—	English counterpart of JP 63-267296	Y
	B31	WO 86/01533	3/13/86	PCT	—	—		Y
	B32	WO 88/00052	1/14/88	PCT	—	—		Y
	B33	WO 88/09344	12/1/88	PCT	—	—		Y
	B34	WO 89/02922	4/6/89	PCT	—	—		Y
	B35	WO 89/09620	10/19/89	PCT	—	—	Abstract in English	N
	B36	WO 90/03801	4/19/90	PCT	—	—		Y
	B37	WO 91/00360	1/10/91	PCT	—	—		Y
	B38	WO 91/04329	04/04/91	PCT	—	—		Y
	B39	WO 91/08298	6/13/91	PCT	—	—		Y
	B40	WO 91/13166	9/5/91	PCT	—	—		Y
	B41	WO 91/14438	10/3/91	PCT	—	—		Y
	B42	WO 92/02240	2/20/92	PCT	—	—		Y
	B43	WO 92/08495	5/29/92	PCT	—	—		Y
	B44	WO 92/08801	5/29/92	PCT	—	—		Y
	B45	WO 92/16562	10/1/92	PCT	—	—		Y
	B46	WO 93/03157	2/18/93	PCT	—	—		Y
<i>✓</i>	B47	WO 93/10229	5/27/93	PCT	—	—		Y

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*3/1/04*

RECEIVED  
NOV 1 9 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 5 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

<i>Del</i>	B48	WO 94/24160	10/27/94	PCT	/	/			Y
	B49	WO 94/25055	11/10/94	PCT	/	/			Y
	B50	WO 95/05468	2/23/95	PCT	/	/			Y
	B51	WO 95/21258	8/10/95	PCT	/	/			Y
	B52	WO 95/28427	10/26/95	PCT	/	/			Y
	B53	WO 95/31483	11/23/95	PCT	/	/			Y
	B54	WO 96/04388	02/15/96	PCT	/	/			Y
	B55	WO 96/05309	2/22/96	PCT	/	/			Y
	B56	WO 96/08570	3/21/96	PCT	/	/			Y
	B57	WO 96/31526	10/10/96	PCT	/	/			Y
	B58	WO 97/00317	1/3/97	PCT	/	/			Y
	B59	WO 97/15666	5/1/97	PCT	/	/			Y
	B60	WO 97/20062	6/5/97	PCT	/	/			Y
	B61	WO 97/24137	7/10/97	PCT	/	/			Y
	B62	WO 97/24440	7/10/97	PCT	/	/			Y
	B63	WO 97/26335	7/24/97	PCT	/	/			Y
	B64	WO 97/30089	8/21/97	PCT	/	/			Y
	B65	WO 97/33617	9/18/97	PCT	/	/			Y
	B66	WO 97/33619	9/18/97	PCT	/	/			Y
	B67	WO 97/34631	9/25/97	PCT	/	/			Y
	B68	WO 97/43316	11/20/97	PCT	/	/			Y
	B69	WO 98/00127	1/8/98	PCT	/	/			Y
	B70	WO 98/06752	2/19/98	PCT	/	/			Y
	B71	WO 98/28427	7/2/98	PCT	/	/			Y
	B72	WO 98/30706	7/16/98	PCT	/	/			Y
	B73	WO 98/46257	10/22/98	PCT	/	/			Y
	B74	WO 98/59244	12/30/98	PCT	/	/			Y
<i>✓</i>	B75	WO 99/02709	01/21/99	PCT	/	/			Y

EXAMINER

*David A. Summers*

DATE CONSIDERED

*3/1/04*RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 6 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

<i>sub</i>	B76	WO 99/03887	01/28/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B77	WO 99/29732	6/17/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B78	WO 99/52562	10/21/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B79	WO 99/53958	10/28/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B80	WO 99/60128	11/25/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B81	WO 99/62944	12/09/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B82	WO 99/66054	12/23/99	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B83	WO 00/11033	3/2/00	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B84	WO 00/34317	06/15/00	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B85	WO 00/40615	7/13/00	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B86	WO 00/68376	11/16/00	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B87	WO 00/69913	11/23/00	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B88	WO 00/78334 A1	12/28/00	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B89	WO 01/07081 A1	2/1/01	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B90	WO 01/10912- A1	2/15/01	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y
	B91	WO 03/015697 A2	2/27/03	PCT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>			Y

EXAM.  
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

<i>sub</i>	C1	Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," <u>Journal of Protein Chemistry</u> , 11:5:433-444.
	C2	Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54:2:83-94.
	C3	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.
	C4	Arenberg et al. (1996), "Interferon- $\gamma$ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992.

EXAMINER

*David A. Shumaker*

DATE CONSIDERED

*3/1/04*RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900



FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

<i>Def</i>	C5	Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Experimental Medicine</u> , 167:612-622
	C6	Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856.
	C7	Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.
	C8	Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831.
	C9	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Mol. Immunol.</u> , 30:379-386.
	C10	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.
	C11	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707.
	C12	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518.
	C13	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Tech. ed., 175-193.
	C14	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221.
	C15	Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Nature</u> , 390:404-407.
	C16	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194.
	C17	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships," <u>The Journal of Biological Chemistry</u> , 268:15983-15993.
	C18	Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164.
	C19	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415.
<i>X</i>	C20	Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138.

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*2/26/04*

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2300



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 8 OF 16

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011 (4006/23)
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.
		SERIAL NO.: 09/780,668      CONF.: 8264
		FILING DATE: February 09, 2001      GROUP: 1644
Day	C21	Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , 173:6:1483-1491.
	C22	Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , 271:46:29461-29467.
	C23	Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272:36:22924-22928.
	C24	Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , 337:525-531.
	C25	Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587.
	C26	Chan et al., (1991), "Induction of Interferon $\gamma$ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.
	C27	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390.
	C28	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355.
	C29	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4/Pseudomonas exotoxin hybrid protein," <u>Nature</u> , 335:370-372.
	C30	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <u>Nature</u> , 339:394-397.
	C31	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159:1:351-358.
	C32	Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993.
	C33	Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.
	C34	Cohen, S. L. et al., (1996), "Human leptin characterization," <u>Nature</u> , 382:589.
	C35	Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621.
	C36	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.
✓	C37	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534.

RECEIVED  
NOV 20 2003  
TECH CENTER 1600/2900

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04





EXPRESS MAIL LABEL NO. EV289510878US

SHEET 9 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

<i>as</i>	C38	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085.
	C39	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398.
	C40	Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , 95:10443-10448.
	C41	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , 161:156-166.
	C42	Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> 31:342-348.
	C43	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:7:2446-2452.
	C44	Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:15552-15558.
	C45	Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," <u>Nature</u> , 395:763-770.
	C46	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342.
	C47	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521.
	C48	Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206.
	C49	Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804.
	C50	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202.
	C51	Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> , 1:1:47-54.
	C52	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , 89:1428-1432.
	C53	Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235.
<i>↓</i>	C54	Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>J. Immunology</u> , 160:2:6195-6203.

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*2/26/04*RECEIVED  
NOV 08 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 10 OF 16

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011 (4006/23)
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.
		SERIAL NO.: 09/780,668      CONF.: 8264
		FILING DATE: February 09, 2001      GROUP: 1644
✓	C55	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , 120:6:2027-2032.
	C56	Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.
	C57	Gren et al., (1983), "A New Type of Leukocytic Interferon," <u>Dokl. Biochem.</u> , 269:91-95.
	C58	Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782.
	C59	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73:8:2081-2805.
	C60	Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148.
	C61	Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Tibtech</u> , 11:42-44.
	C62	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotech.</u> , 1:95-105.
	C63	Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," <u>Journal of Immunology</u> , 157:7:3165-3170.
	C64	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11:6:636.
	C65	He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both $\alpha$ - and P-Selectin," <u>J. Immunol.</u> , 1029-1035.
	C66	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcYRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97:2:331-338.
	C67	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunol.</u> , 158:4381-4388.
	C68	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci.</u> , 83:18: 7059-7063.
	C69	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58.
	C70	Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7:2:159-167.
	C71	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17:6:1656-1664.
↓	C72	Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675.
EXAMINER <i>David A. Saunders</i>		DATE CONSIDERED <i>4/26/04</i>

RECEIVED  
NOV 10 2003  
TECH CENTER  
1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 11 OF 16

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011 (4006/23)
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.
		SERIAL NO.: 09/780,668      CONF.: 8264
		FILING DATE: February 09, 2001      GROUP: 1644
<input checked="" type="checkbox"/>	C73	Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869.
<input type="checkbox"/>	C74	Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , 28:9:1027-1037.
<input type="checkbox"/>	C75	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096:4:345-354 (Abstract).
<input type="checkbox"/>	C76	Hornick et al., (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.
<input type="checkbox"/>	C77	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.
<input type="checkbox"/>	C78	Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14:4:1779-1789.
<input type="checkbox"/>	C79	Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281.
<input type="checkbox"/>	C80	Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , 348:555-557.
<input type="checkbox"/>	C81	Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , 321:6069:522-525.
<input type="checkbox"/>	C82	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731.
<input type="checkbox"/>	C83	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci.</u> , 83:4479-4483.
<input type="checkbox"/>	C84	Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-microglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci.</u> , 93:11:5512-5516.
<input type="checkbox"/>	C85	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci.</u> , 88:11120-11123.
<input type="checkbox"/>	C86	Kappel et al., (1992), "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> , 3:548-553.
<input type="checkbox"/>	C87	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcγ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160:6:1686-1701.
<input checked="" type="checkbox"/>	C88	Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," <u>Journal Immunology</u> , 158:9:4137-4144.

EXAMINER

David A. Savender

DATE CONSIDERED

4/26/04

RECEIVED  
NOV 10 2003  
TECH CENTER  
1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 12 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

✓	C89	Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84.
✓	C90	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 81:7922-7926.
✓	C91	Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NCI/Endostatin Domain," <u>Journal of Cell Biology</u> , 152:6:1233-1246.
✓	C92	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268:31:23311-23317.
✓	C93	Lazar et al., (1988), "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8:3:1247-1252.
✓	C94	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698.
✓	C95	Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," <u>Nature Biotechnology</u> , 15:1:35-40.
✓	C96	Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , 174:3:561-569.
✓	C97	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 82:8648-8652.
✓	C98	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398.
✓	C99	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 91:10:3730-3736.
✓	C100	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11:6:495-500.
✓	C101	Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Ther.</u> , 80:3:277-292.
✓	C102	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91:5:1706-1715.
✓	C103	Lode et al., (1999), "Synergy between an antiangiogenic integrin $\alpha_v$ antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci.</u> , 96:1591-1596.
✓	C104	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci.</u> , 96:8591-8596.
✓	C105	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29:2:117-120.

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2900



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 13 OF 16

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011 (4006/23)
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.
		SERIAL NO.: 09/780,668      CONF.: 8264
		FILING DATE: February 09, 2001      GROUP: 1644
gus	C106	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84:8:2457-2466.
	C107	Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," <u>Journal of Biological Chemistry</u> , 267:36:26166-26171.
	C108	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146.
	C109	Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158:5:2211-2217.
	C110	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895.
	C111	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> 7:145-173.
	C112	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> 247:979-994.
	C113	Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20:4:473-492.
	C114	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related $\alpha$ -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci.</u> , 83:8258-8262.
	C115	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , 123-140.
	C116	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13:17:6361-6373.
	C117	Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458.
	C118	Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> , 96:3137-3142.
	C119	Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608.
	C120	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328.
	C121	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , 2:6:689-692.

EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04

RECEIVED  
NOV 10 2003  
TECH CENTER 1600/2800



FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

28	C122	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285.
	C123	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264:26:15157-15160.
	C124	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438.
	C125	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , 163:166-178.
	C126	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal of Immunology</u> , 142:10:3662-3667.
	C127	Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Research</u> , 59:1036-1040.
	C128	Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , 94:20:10889-10894.
	C129	Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 27-53.
	C130	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , 7:2:S99-S106.
	C131	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , 343:1177-1183.
	C132	Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor $\alpha$ and $\beta$ chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347.
	C133	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition, 8:3-8.4.
	C134	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , 9:2:58-62.
	C135	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> , 2:3:159-173.
	C136	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705.
	C137	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , 17:15:4249-4256.
✓	C138	Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the $\alpha$ chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.


EXAMINER

David A. Saunders

DATE CONSIDERED

2/26/04

 RECEIVE  
 NOV 10 2003  
 TECH CENTER 1600/2800



FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011 (4006/23)
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.
		SERIAL NO.: 09/780,668 CONF.: 8264
		FILING DATE: February 09, 2001 GROUP: 1644
<i>guf</i>	C139	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci.</u> , 84:6904-6908.
	C140	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , 148:11:3433-3340.
	C141	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with ectoposide phosphate," <u>Proc. Natl. Acad. Sci.</u> , 85:13:4842-4846.
	C142	Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.
	C143	Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>Journal of Immunology</u> , 163:5020-5028.
	C144	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon- $\lambda$ and is not blocked by human IgG," <u>Journal of Immunology</u> , 137:11:3378-3382.
	C145	Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503.
	C146	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci.</u> , 87:5322-5326.
	C147	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334.
	C148	Stevenson et al., (1997), "Conjugation of Human Fc $\gamma$ in Closed-Hinge or Open-Hinge Configuration to Fab $\gamma$ and Analogous Ligands," <u>Journal of Immunology</u> , 158:2242-2250.
	C149	Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Research</u> , 60:247-267.
	C150	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , 302:305-309.
	C151	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , 143:8:2595-2601.
	C152	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , 178:2:661-667.
	C153	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925.
	C154	<u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 <sup>th</sup> ed. 1999).
<i>✓</i>	C155	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48:5:1119-1123

EXAMINER

*Daniel A. Spencer*

DATE CONSIDERED

*2/26/04*RECEIVED  
NOV 10 2003  
TECH CENTER 1600/23



EXPRESS MAIL LABEL NO. EV289510878US

SHEET 16 OF 16

FORM PTO - 1449

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011 (4006/23)

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF.: 8264

FILING DATE: February 09, 2001 GROUP: 1644

✓	C156	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168
✓	C157	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027.
✓	C158	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470.
✓	C159	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , 44:681-687.
✓	C160	Verhoeven et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536.
✓	C161	Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:1:12-20.
✓	C162	Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:9:3662-3672.
✓	C163	Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82:1507-1516.
✓	C164	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , 43:319-324.
✓	C165	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <u>Protein Engineering</u> , 1:6:493-498.
✓	C166	Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor 1c Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>Journal Immunology</u> , 151: 6602-6607.
✓	C167	Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.
✓	C168	Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955.
✓	C169	Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," <u>Journal of Immunology</u> , 154:5590-5600.
✓	C170	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269:3469-3474.

2698127

EXAMINER <i>David A. Saunders</i>	DATE CONSIDERED <i>2/26/04</i>
-----------------------------------	--------------------------------

RECEIVED  
NOV 10 2003  
TECH CENTER 1800/2800





FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

## U.S. PATENT DOCUMENTS

EXAM. INT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>2948</i>	A60	4,703,008	10/27/87	Lin	435	240.2	11/30/84
	A61	5,457,038	10/10/95	Trinchieri <i>et al.</i>	435	69.52	9/18/90
	A62	5,441,868	8/15/95	Lin	435	69.4	10/23/87
	A63	5,547,933	8/20/96	Lin	514	8	6/7/95
	A64	5,618,698	4/8/97	Lin	435	69.4	6/6/95
	A65	5,650,150	7/22/97	Gillies	424	134.1	7/27/94
	A66	5,688,679	11/18/97	Powell	435	240.2	10/6/93
	A67	5,723,125	3/3/98	Chang <i>et al.</i>	424	134.1	9/25/96
<i>of record</i>	A68	5,756,349	5/26/98	Lin	435	325	6/6/95
	A69	<del>5,908,626</del>	<del>6/1/99</del>	<del>Chang <i>et al.</i></del>	<del>424</del>	<del>134.1</del>	<del>12/19/97</del>
<i>2948</i>	A70	5,955,422	9/21/99	Lin	514	8	8/2/93
	A71	6,100,387	8/8/00	Herrmann <i>et al.</i>	536	23.4	2/28/97
	A72	6,231,536	5/15/01	Lentz	604	5.04	5/21/99
	A73	6,284,536	9/4/01	Morrison <i>et al.</i>	435	328	4/20/99
	A74	6,335,176 B1	1/1/02	Inglese <i>et al.</i>	435	7.72	10/16/98
	A75	6,340,742	1/22/02	Burg <i>et al.</i>	530	351	6/28/00
	A76	6,444,792	9/3/02	Gray <i>et al.</i>	530	387.3	1/8/99
	A77	6,475,717 B1	11/5/02	Enssle <i>et al.</i>	435	5	7/25/97
	A78	6,485,726 B1	11/26/02	Blumberg <i>et al.</i>	424	178.1	7/24/98
	A79	6,506,405	1/14/03	Desai <i>et al.</i>	424	450	8/1/00
	A80	6,583,272	6/24/03	Bailon	530	397	6/27/00
	A81	6,586,398	7/1/03	Kinstler <i>et al.</i>	514	12	4/7/00
	A82	6,617,135	9/9/03	Gillies <i>et al.</i>	435	69.7	8/9/00
	A83	2001/0053539 A1	12/20/01	Lauffer <i>et al.</i>	435	69.1	4/6/99

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/6/05*



FORM PTO-1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>du</i>	A84	2002/0081664 A1	6/27/02	Lo <i>et al.</i>	435	69.5	10/11/01
	A85	2002/0142374 A1	10/3/02	Gallo <i>et al.</i>	435	69.1	8/17/99
	A86	2002/0147311 A1	10/10/02	Gillies <i>et al.</i>	530	387.1	2/9/01
	A87	2002/0192222 A1	12/19/02	Blumberg <i>et al.</i>	424	178.1	8/8/02
	A88	2002/0193570 A1	12/19/02	Gillies <i>et al.</i>	530	351	12/4/01
	A89	2003/0003529 A1	1/2/03	Bayer	435	68.1	7/19/02
	A90	2003/0044423 A1	3/6/03	Gillies <i>et al.</i>	424	192.1	3/7/02
	A91	2003/0049227 A1	3/13/03	Gillies <i>et al.</i>	424	85.1	6/29/01
	A92	2003/0105294 A1	6/5/03	Gillies <i>et al.</i>	530	351	2/24/99
	A93	2003/0012789 A1	1/6/03	Blumberg <i>et al.</i>	424	145.1	8/8/02
	A94	2003/0157054 A1	8/21/03	Gillies <i>et al.</i>	424	85.1	5/3/02
	A95	2003/0166163 A1	9/4/03	Gillies	435	69.52	12/4/02
	A96	2003/0166877 A1	9/4/03	Gillies <i>et al.</i>	530	395	3/29/02

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/7/05*



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

## FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>ds</i>	B92	1 088 888 A1	4/04/01	EP	—	—	5/13/99	N	Y
<i>ds</i>	B93	WO 96/18412	6/20/96	PCT	—	—	12/12/94	N	Y
<i>ds</i>	B94	WO 97/00319	1/03/97	PCT	—	—	6/11/96	N	Y
<i>ds</i>	B95	WO 99/43713	9/03/99	PCT	—	—	2/24/99	N	Y
<i>ds</i>	B96	WO 00/24893	5/04/00	PCT	—	—	10/18/99	N	
	B97	WO 01/36489 A2	5/25/01	PCT	—	—	11/03/00	N	Y
	B98	WO 01/58957 A2	8/16/01	PCT	—	—	2/09/01	N	Y
	B99	WO 02/02143 A2	1/10/02	PCT	—	—	06/29/01	N	Y
	B100	WO 02/066514 A2	8/29/02	PCT	—	—	2/18/02	Y	Y
	B101	WO 02/072605 A2	9/19/02	PCT	—	—	3/07/02	N	Y
	B102	WO 02/079232 A2	10/10/02	PCT	—	—	3/30/02	N	Y
	B103	WO 02/079415 A2	10/10/02	PCT	—	—	3/29/02	N	Y
	B104	WO 02/090566 A2	11/14/02	PCT	—	—	5/03/02	N	Y
	B105	WO 03/048334 A2	6/12/03	PCT	—	—	12/04/02	N	Y
<i>✓</i>	B106	WO 03/077834 A2	9/25/03	PCT	—	—	7/03/02	N	Y

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/6/05*



<b>FORM PTO - 1449</b>		<b>ATTORNEY DOCKET NO.: LEX-011</b>	
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO.: 09/780,668</b>	
		<b>EXAMINER: David A. Saunders</b>	
		<b>FILING DATE: February 9, 2001 GROUP: 1644</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
gus	C171	Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30:105-108.	
	C172	Balova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263.	
	C173	Becker et al., (1996), "Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy," <u>J Clin Invest</u> , 98(12):2801-4.	
	C174	Becker et al., (1996), "T Cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy," <u>J Exp Med</u> , 183(50):2361-6.	
	C175	Bitonti et al., (2002), "Transépithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.	
	C176	Briggs et al., (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227:1385-1388.	
	C177	Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.	
	C178	Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7.	
	C179	Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.	
	C180	Davis et al., (2003), "Immunocytokines: amplification of anti-cancer immunity," <u>Cancer Immunol Immunother</u> 52:297-308	
	C181	Dolman et al., (1998), "Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy," <u>Clin Cancer Res</u> , 4(10):2551-7.	
	C182	Duncan et al., (1988), "The binding site for C1q on IgG," <u>Nature</u> , 332:738-740.	
	C183	Egrie et al., (2001), "Development and characterization of novel erythropoiesis stimulating protein (NESP)," <u>Nephrol. Dial. Transplant</u> , 16:3-13.	
↓	C184	Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.	
	C185	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric (Fab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:72446-2452.	

<b>EXAMINER</b> David A. Saunders	<b>DATE CONSIDERED</b> 7/6/05
-----------------------------------	-------------------------------

DUPLICATE  
OF C43



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C186	Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85:1229-1236.
	C187	Frost et al., (1997), "A Phase I/II Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 Children with Refractory Neuroblastoma", <u>Cancer</u> , 80:317-33.
	C188	Gan et al., (1999), "Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins," <u>Clin Diagn Lab Immunol.</u> , 6(2):236-42.
	C189	Gillies et al., (1991), "Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody," <u>Hybridoma</u> , 10(3):347-56.
	C190	Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166.
	C191	Gillies et al., (2002), "Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer," <u>Cancer Immunol Immunother.</u> , 51(8):449-60.
	C192	Gillies et al., (2002), "Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6.
	C193	Greene et al., (1975), "Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells", <u>Proc. Natl. Acad. Sci. USA</u> , 72:4923-4927.
	C194	Hammerling et al., (1996), "In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469.
	C195	Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol Med.</u> , 85:123-31.
	C196	Haraguchi, (1994), "Isolation of GD3 synthase gene by expression cloning of GM3 $\alpha$ -2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9.
	C197	Harris, (1995), "Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture," <u>J. Chromatogr. A</u> , 705:129-134.
	C198	Hezaveh et al, (2001), "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1," <u>J. Virol.</u> , 75(24):12161-8.
	C199	Idusogie et al., (2000), "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-84.
	C200	Imboden et al., (2001), "The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy," <u>Cancer Res.</u> , 61(4):1500-7.

EXAMINER <i>David A. Saunders</i>	DATE CONSIDERED <i>7/6/05</i>
-----------------------------------	-------------------------------



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
<i>dal</i>	C201 Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.
	C203 Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131.
	C204 Kendra et al., (1999), "Pharmacokinetics and Stability of the ch 14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunotherapy</u> , 48:219-229.
	C205 King et al., (2003), "A Phase I/II clinical trial of the immunocytokine hu14.18-IL2 (EMD 273063) in patients with melanoma," Author's manuscript dated June 6, 2003.
	C206 Kitamura et al., (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.
	C207 Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma", <u>J. Clin. Oncol.</u> , 19:4189-94.
	C208 Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.
	C209 Lode et al., (1997), "Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94.
	C210 Lode et al., (2000), "What to do with targeted IL-2," <u>Drugs Today</u> , 36(5):321-36.
	C211 Lode et al., (2000), "Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.
	C212 Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70.
	C213 Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis," <u>Blood</u> , 99(11):4166-73.
	C214 Mueller et al., (1997), "Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells," <u>Molecular Immunology</u> , 34(6):441-452.
	C215 Mullins et al., (1997), "Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities," <u>Cancer Immunol Immunother.</u> , 45:20-28.
<i>↓</i>	C216 Naramura et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells," <u>Immunol Lett.</u> , 39(1):91-9.

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/16/05*



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
<i>del</i>	C217 Neal et al., (2003), "NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy," <i>Cancer Immunol Immunother.</i> , Pub. Med ID: 14504825.
	C218 Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" pp. 433-440 and 492-495.
	C219 Niethammer et al., (2001) "An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevent growth and dissemination of Lewis Lung carcinoma in CEA transgenic mice," <i>Vaccine</i> , 20(3-4):421-9.
	C220 Niethammer et al., (2001) "Targeted Interleukin 2 therapy enhances protective immunity induced by an autologous murine melanoma," <i>Cancer Res.</i> , 61(16):6178-84.
	C221 Nimitz et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in recombinant BHK-21 Cells," <i>Eur. J. Biochem.</i> , 213:39-56.
	C222 Pancook et al., (1996), "Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2," <i>Cancer Immunol Immunother.</i> , 42(2):88-92.
	C223 Park et al., (2000), "Efficiency of promoter and cell line in high-level expression of erythropoietin," <i>Biotechnol. Appl. Biochem.</i> , 32:167-172.
	C224 Reisfeld et al., (1996), "Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy," <i>J Clin Lab Anal.</i> , 10(3):160-6.
	C225 Reisfeld et al., (1996), "Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein," <i>Cancer Res.</i> , 56(8):1707-12.
	C226 Ruchtmann et al., (2001), "MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma," <i>Cancer Res.</i> , 61(23):8498-503.
	C227 Sabzevari et al., (1994), "A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human severe combined immunodeficiency mice," <i>Proc Natl Acad Sci USA</i> , 91(20):9626-30.
	C228 Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <i>Journal of National Cancer Institute</i> , 93:1204-1214.
	C229 Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <i>J. Biol. Chem.</i> , 278:3466-3473.
✓	C230 Spickermann et al., (2002), "Receptor-mediated immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <i>J. Exp. Med.</i> , 196:303-310.

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/6/05*



FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
<i>Yes</i>	C231	Strom et al., (1996), "Therapeutic Approach to Organ Transplantation", <u>Blackwell Science</u> , Chapter 36, pp. 451-456.
	C232	Syed et al., (1998), "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," <u>Nature</u> , 395:511-516.
	C233	Thommesen et al., (2000), "Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation", <u>Mol. Immunol.</u> , 37(16):995-1004.
	C234	Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.
	C235	Xiang et al., (1998), "Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases," <u>Cancer Res.</u> , 58(17):3918-25.
	C236	Xiang et al., (1999) "T Cell memory against colon carcinoma is long-lived in the absence of antigen," <u>J Immunol.</u> , 163(7):3676-83.
	C237	Xiang et al., (2001), "A dual function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice," <u>J Immunol.</u> , 167(8):4560-5.
	C238	Xiang et al., (2001), "Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice," <u>Clin Cancer Res.</u> , 7(3 Suppl):856s-864s.
	C239	Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.8 in Patients With Refractory Neuroblastoma and Osteosarcoma", <u>J. Clin. Oncol.</u> , 16:2169-80.
<i>✓</i>	C240	Zagoridon et al., (1999), "Potentiation of antitumor effect of IL-12 in combination with paclitaxel in murine melanoma model in vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648.

3025201\_1

EXAMINER <i>David A. Saunders</i>	DATE CONSIDERED <i>7/6/05</i>
-----------------------------------	-------------------------------



IDS FILED 9/28/04

<b>FORM PTO - 1449</b>  <b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>					<b>ATTORNEY DOCKET NO.: LEX-011</b>  <b>APPLICANT(S): Gillies et al.</b>  <b>SERIAL NO.: 09/780,668</b>  <b>EXAMINER: David A. Saunders</b>  <b>FILING DATE: February 9, 2001 GROUP: 1644</b>				
<b>U.S. PATENT DOCUMENTS</b>									
EXAM. INT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE			
A97	5,601,819	2/11/97	Wong et al.	—	—				
A98	5,891,680	4/6/99	Lieschke et al.	—	—				
A99	5,994,104	11/30/99	Anderson et al.	—	—				
A100	6,429,199	8/6/02	Krieg et al.	—	—				
A101	6,500,641	12/31/02	Chen et al.	—	—				
A102	6,551,592	4/22/03	Lindhofer et al.	—	—				
A103	6,646,113	11/11/03	Dreyfuss et al.	—	—				
A104	2002/0037558	3/28/02	Lo et al.	—	—				
A105	2002/0146388	10/10/02	Gillies	—	—				
A106	2003/0139365	7/24/03	Lo et al.	—	—				
A107	2003/0139575	7/24/03	Gillies	—	—				
A108	2004/0013640	1/22/04	Zardi et al.	—	—				
A109	2004/0033210	2/19/04	Gillies	—	—				
A110	2004/0043457	3/4/04	Schumacher et al.	—	—				
A111	2004/0053366	3/18/04	Lo et al.	—	—				
A112	2004/0072299	4/15/04	Gillies et al.	—	—				
A113	2004/0082039	4/29/04	Gillies et al.	—	—				
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAM. INT.	DOCUMENT NUMBER	DATE	COUNT RY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)	
B107	WO 93/20185	10/14/93	PCT	—	—				
<b>EXAMINER</b> <i>David A. Saunders</i>				<b>DATE CONSIDERED</b> <i>7/5/05</i>					

**THIRD SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/780,668

EXAMINER: David A. Saunders

FILING DATE: February 9, 2001 GROUP: 1644

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
<i>DS</i>	C241	Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204.
	C242	Conner et al., (2004), "Ex vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer," <u>J. Immunotherapy</u> , 27:211-219.
	C243	de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co.
	C244	Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217.
	C245	Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491.
	C246	Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713.
	C247	Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071.
	C248	Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267.
	C249	Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Research</u> , 2(12):1951-1959.
	C250	Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142.
	C251	Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729.
	C252	Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)," <u>J. Immunotherapy</u> , 27:232-239.
<i>✓</i>	C253	Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128.




EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/5/05*



<b>FORM PTO - 1449</b>		<b>ATTORNEY DOCKET NO.: LEX-011</b>	
<b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO.: 09/780,668</b>	
		<b>EXAMINER: David A. Saunders</b>	
		<b>FILING DATE: February 9, 2001 GROUP: 1644</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C254	Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696.	
	C255	Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386	
	C256	Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705.	
	C257	Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349.	
	C258	Pertl et al., (2003), "Immunotherapy with a Posttranscriptionally Modified DNA Vaccine Induces Complete Protection Against Metastatic Neuroblastoma," <u>Blood</u> , 101(2):649-654.	
	C259	Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212	
	C260	Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antib. Hybridomas</u> , 3:19-24.	
	C261	Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor $\alpha$ ," <u>J. Exp. Med.</u> , 179:1109-1118.	
	C262	Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133.	
	C263	Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," <u>American Society of Clinical Oncology Program/Proceedings</u> , 20(Part 1):259a.	
	C264	Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846.	
	C265	Gurewich et al., (1988), "Characterization of the Intrinsic Fibrinolytic Properties of Pro-urokinase through a Study of Plasmin-resistant Mutant Forms Produced by Site-specific Mutagenesis of Lysine <sup>158</sup> ," <u>J. Clin. Invest.</u> , 82:1956-1962.	
	C266	Miyake et al., (1988), "Synthesis of Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator Variants Resistant to Plasmin and Thrombin," <u>J. Biochem.</u> , 104:643-647.	
<b>EXAMINER</b> 		<b>DATE CONSIDERED</b> 7/5/05	




<b>FORM PTO - 1449</b>		<b>ATTORNEY DOCKET NO.: LEX-011</b>	
<b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO.: 09/780,668</b>	
		<b>EXAMINER: David A. Saunders</b>	
		<b>FILING DATE: February 9, 2001 GROUP: 1644</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
<i>David</i>	C267	Nelles et al., (1987), "Characterization of Recombinant Human Single Chain Urokinase-type Plasminogen Activator Mutants Produced by Site-specific Mutagenesis of Lysine <sup>158</sup> ," <u>The Journal of Biological Chemistry</u> , 262(12):5682-5689.	
<b>EXAMINER</b>	<i>David A. Saunders</i>		<b>DATE CONSIDERED</b> <i>7/5/05</i>

3113305\_1

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>dal</i>	A114	4,522,811	6/11/85	Eppstein <i>et al.</i>	—	—	
<i>lc</i>	A115	4,667,016	5/19/87	Lai <i>et al.</i>	—	—	
	A116	4,732,683	3/22/88	Georgiades <i>et al.</i>	—	—	
	A117	4,737,462	4/12/88	Mark <i>et al.</i>	—	—	
	A118	4,975,369	12/4/90	Beavers <i>et al.</i>	—	—	
	A119	5,082,658	1/21/92	Palladino	—	—	
	A120	5,091,513	2/25/92	Huston <i>et al.</i>	—	—	
	A121	5,399,346	3/21/95	Anderson <i>et al.</i>	—	—	
	A122	5,428,130	6/27/95	Capon <i>et al.</i>	—	—	
	A123	5,480,981	1/2/96	Goodwin <i>et al.</i>	—	—	
	A124	5,589,466	12/31/96	Felgner <i>et al.</i>	—	—	
	A125	5,614,184	3/25/97	Sytkowski <i>et al.</i>	—	—	
	A126	5,712,120	1/27/98	Rodriguez <i>et al.</i>	—	—	
	A127	5,738,852	4/14/98	Robinson <i>et al.</i>	—	—	
	A128	5,795,779	8/18/98	McCormick <i>et al.</i>	—	—	
	A129	5,827,703	10/27/98	Debs <i>et al.</i>	—	—	
	A130	5,837,821	11/17/98	Wu <i>et al.</i>	—	—	
	A131	5,888,773	3/30/99	Jost <i>et al.</i>	—	—	
	A132	6,281,010	8/28/01	Gao <i>et al.</i>	—	—	
	A133	6,291,158	9/18/01	Winter <i>et al.</i>	—	—	
	A134	6,627,615	9/30/03	Debs <i>et al.</i>	—	—	
<i>↓</i>	A135	2004/0180035	9/16/04	Gillies <i>et al.</i>	—	—	

EXAMINER


*David A. Saunders*

DATE CONSIDERED

*7/7/05*

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>gn</i>	B108	0 344 134 B1	01/19/94	EP	—	—			
	B109	0 428 267 B1	12/11/96	EP	—	—			
	B110	0 428 596 B1	4/17/96	EP	—	—			
	B111	0 433 827 B1	3/14/98	EP	—	—			
	B112	0 519 596 A1	12/23/92	EP	—	—			
	B113	0 668 351 B1	9/22/99	EP	—	—			
	B114	0 699 755 B1	4/28/04	EP	—	—			
	B115	2 188 638 A	10/7/87	GB	—	—			
	B116	WO 92/10755	6/25/92	PCT	—	—			
	B117	WO 94/25609	11/10/94	PCT	—	—			
	B118	WO 96/40792	12/19/96	PCT	—	—			
	B119	WO 98/52976	11/26/98	PCT	—	—			
<i>✓</i>	B120	WO 00/01822	1/13/00	PCT	—	—			

EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/7/05*

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011	
INFORMATIONAL DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
JAN 19 2005		SERIAL NO.: 09/780,668	CONF. NO.: 8264
PATENT & TRADEMARK OFFICE		FILING DATE: February 9, 2001	GROUP: 1644
OTHER ART, JOURNAL ARTICLES ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
<i>see</i>	C268	Aichele <i>et al.</i> , (1994), "Peptide-Induced T-Cell Tolerance to Prevent Autoimmune Diabetes in a Transgenic Mouse Model," <u>Proc. Natl. Acad. Sci. USA</u> , 91:444-448.	
	C269	Altschul <i>et al.</i> , (1990), "Basic Local Alignment Search Tool," <u>J. Mol. Biol.</u> , 215:403-10.	
	C270	Altschul <i>et al.</i> , (1997), "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," <u>Nucleic Acids Res.</u> , 25(17):3389-402.	
	C271	Anderson <i>et al.</i> , (1980), "Characterization of the Fc Receptor for IgG on a Human Macrophage Cell Line U937," <u>J. Immunol.</u> , 125:2735-41.	
	C272	Anderson <i>et al.</i> , (1994), "Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2," <u>Clin. Pharmacokinet.</u> , 27(1):19-31.	
	C273	Baici <i>et al.</i> , (1980), "Kinetics of the Different Susceptibilities of the Four Human Immunoglobulin G Subclasses to Proteolysis by Human Lysosomal Elastase," <u>Scand. J. Immunol.</u> , 12(1):41-50.	
	C274	Barbulescu <i>et al.</i> , (1998), "IL-12 and IL-18 Differentially Regulate the Transcriptional Activity of the Human IFN- $\gamma$ Promoter in Primary CD4+ T Lymphocytes," <u>J. Immunol.</u> , 160:3642-7.	
	C275	Becker <i>et al.</i> , (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci. USA</u> , 93:7826-7831.	
	C276	Bednarek <i>et al.</i> , (1991), "Soluble HLA-A2.1 Restricted Peptides that are Recognized by Influenza Virus Specific Cytotoxic T Lymphocytes," <u>J. Immunol. Methods</u> , 139:41-47.	
	C277	Benacerraf <i>et al.</i> , (1959), "The Clearance of Antigen Antibody Complexes from the Blood by the Reticuloendothelial System," <u>J. Immunol.</u> , 82:131-7.	
	C278	Bohm, (1994), "On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure," <u>J. Comput. Aided Mol. Des.</u> , 8:623-32.	
	C279	Bohm, (1994), "The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure," <u>J. Comput. Aided Mol. Des.</u> , 8:243-56.	
	C280	Bohm, (1998), "Prediction of Binding Constants of Protein Ligands: A Fast Method for the Prioritization of Hits Obtained from De Novo Design or 3D Database Search Programs," <u>J. Comput. Aided Mol. Des.</u> , 12(4):309-23.	
	C281	Boshart <i>et al.</i> , (1985), "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," <u>Cell</u> , 41:521-530.	
	C282	Boulianne <i>et al.</i> , (1984), "Production of Functional Chimaeric Mouse/Human Antibody," <u>Nature</u> , 312:643-6.	

EXAMINER <i>Daniel S. Saunders</i>	DATE CONSIDERED <i>7/5/05</i>
------------------------------------	-------------------------------

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

JAN 18 2005



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
<i>Jul</i>	C283 Bourgois <i>et al.</i> , (1974), "Determination of the Primary Structure of a Mouse IgG2a Immunoglobulin Amino Acid Sequence of the Fc Fragment: Implications for the Evolution of Immunoglobulin Structure and Function," <u>Eur. J. Biochem.</u> , 43:423-35.
	C284 Brambell <i>et al.</i> , (1964), "A Theoretical Model of Gamma-Globulin Catabolism," <u>Nature</u> , 203:1352-54.
	C285 Brazolot Millan <i>et al.</i> , (1998), "Cpg DNA Can Induce Strong TH1 Humoral and Cell-Mediated Immune Responses against Hepatitis B Surface Antigen in Young Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 95:15553-8.
	C286 Brekke <i>et al.</i> , (1994), "Human IgG Isotype-Specific Amino Acid Residues Affecting Complement-Mediated Cell Lysis and Phagocytosis," <u>Eur. J. Immunol.</u> , 24:2542-2547.
	C287 Brem <i>et al.</i> , (1993), "The Combination of Antiangiogenic Agents to Inhibit Primary Tumor Growth and Metastasis," <u>J. Pediatr. Surg.</u> , 28:1253-7.
	C288 Brocklebank <i>et al.</i> , (2001), "Enumeration of CD34+ Cells in Cord Blood: A Variation on a Single-Platform Flow Cytometric Method Based on the ISHAGE Gating Strategy," <u>Cytometry</u> , 46(4):254-61.
	C289 Brooks <i>et al.</i> , (1983), "CHARMM: A Program for Macromolecular Energy Minimization and Dynamics Calculations," <u>J. Comput. Chemistry</u> , 4:187-217.
	C290 Broudy <i>et al.</i> , (1988), "Recombinant Human Erythropoietin: Purification and Analysis of Carbohydrate Linkage," <u>Arch. Biochem. Biophys.</u> , 265:329-36.
	C291 Bubenik <i>et al.</i> , (1995), "Interleukin-2 Gene Therapy of Residual EL-4 Leukaemia Potentiates the Effect of Cyclophosphamide Pretreatment," <u>J. Cancer Res. Clin. Oncol.</u> , 121:39-43.
	C292 Bumol <i>et al.</i> , (1982), "Unique Glycoprotein-Proteoglycan Complex Defined by Monoclonal Antibody on Human Melanoma Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 79:1245-9.
	C293 Camemolla <i>et al.</i> , (1989), "A Tumor-Associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors," <u>J. Cell. Biol.</u> , 108:1139-1148.
	C294 Camemolla <i>et al.</i> , (1992), "The Inclusion of the Type III Repeat ED-B in the Fibronectin Molecule Generates Conformational Modifications that Unmask a Cryptic Sequence," <u>J. Biol. Chem.</u> , 267(34):24689-24692.
	C295 Cazzola <i>et al.</i> , (1998), "Red Blood Cell Precursor Mass as an Independent Determinant of Serum Erythropoietin Level," <u>Blood</u> , 91:2139-45.
	C296 Chan <i>et al.</i> , (1992), "Mechanisms of IFN-Gamma Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12). Role of Transcription and mRNA Stability in the Synergistic Interaction Between NKSF and IL-2," <u>J. Immunol.</u> , 148:92-98.
<i>✓</i>	C297 Chappel <i>et al.</i> , (1991), "Identification of the Fc Gamma Receptor Class I Binding Site In Human IgG Through Use of Recombinant IgG1/IgG2 Hybrid and Point-Mutated Antibodies," <u>Proc. Natl. Acad. Sci. USA</u> , 88(20):9036-40.


EXAMINER

*David A. Saunders*

DATE CONSIDERED

*7/5/05*



FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011	
		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 09/780,668	CONF. NO.: 8264
		FILING DATE: February 9, 2001	GROUP: 1644
OTHER ART, JOURNAL ARTICLES ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
Jes	C298	Cheetham, (1998), "NMR Structure of Human Erythropoietin and a Comparison with its Receptor Bound Conformation," <u>Nat. Struct. Biol.</u> , 5:861-6.	
	C299	Ciardiello <i>et al.</i> , (1996), "Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A," <u>J. Natl. Cancer Inst.</u> , 88:1770-6.	
	C300	Cirulli <i>et al.</i> , (1998), "KSA Antigen Ep-CAM Mediates Cell-Cell Adhesion of Pancreatic Epithelial Cells: Morphoregulatory Roles in Pancreatic Islet Development," <u>J. Cell Biol.</u> , 140:1519-34.	
	C301	Cohen <i>et al.</i> , (1998), "An Artificial Cell-Cycle Inhibitor Isolated from a Combinatorial Library," <u>Proc. Natl. Acad. Sci. USA</u> , 95:14272-7.	
	C302	Congote <i>et al.</i> , (1984), Abstract 364 in "Proceedings 7 <sup>th</sup> Intl. Congress of Endocrinology," Quebec City, Quebec.	
	C303	Congote, (1983), "Isolation of Two Biologically Active Peptides, Erythrotropin I and Erythrotropin II from Fetal Calf Intestine," <u>Biochem. Biophys. Res. Commun.</u> , 115(2):477-83.	
	C304	Congote, (1984), "Extraction from Fetal Bovine Serum of Erythrotropin, an Erythroid Cell-Stimulating Factor," <u>Anal. Biochem.</u> , 140:428-33.	
	C305	Cosenza <i>et al.</i> , (1997), "Disulfide Bond Assignment in Human Interleukin-7 by Matrix-Assisted Laser Desorption/Ionization Mass Spectroscopy and Site-Directed Cysteine to Serine Mutational Analysis," <u>J. Biol. Chem.</u> , 272:32995-3000.	
	C306	Cunningham <i>et al.</i> , (1989), "High-Resolution Epitope Mapping of Hgh-Receptor Interactions by Alanine-Scanning Mutagenesis," <u>Science</u> , 244:1081-85.	
	C307	Curiel <i>et al.</i> , (1991), "Adenovirus Enhancement of Transferrin-Polylysine-Mediated Gene Delivery," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8850-4.	
	C308	Dauber-Osguthorpe <i>et al.</i> , (1988), "Structure and Energetics of Ligand Binding to Proteins: Escherichia Coli Dihydrofolate Reductase-Trimethoprim, A Drug-Receptor System," <u>Proteins</u> , 4(1):31-47.	
	C309	Daugherty <i>et al.</i> , (1991), "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <u>Nucleic Acid Res.</u> , 19:2471-2476.	
	C310	De Bruijn <i>et al.</i> , (1995), "Phagocyte-Induced Antigen-Specific Activation of Unprimed CD8+ T Cells in Vitro," <u>Eur. J. Immunol.</u> , 25:1274-85.	
	C311	Delorme <i>et al.</i> , (1992), "Role of Glycosylation on the Secretion and Biological Activity of Erythropoietin," <u>Biochemistry</u> , 31:9871-6.	
✓	C312	Desai <i>et al.</i> , (1992), "IL-12 Receptor. II. Distribution and Regulation of Receptor Expression," <u>J. Immunol.</u> , 148:3125-32.	

EXAMINER <i>David A. Sander</i>	DATE CONSIDERED <i>7/5/05</i>
---------------------------------	-------------------------------

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644


## OTHER ART, JOURNAL ARTICLES ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
<i>Dr</i>	C313 Donnelly <i>et al.</i> , (1993), "Targeted Delivery of Peptide Epitopes to Class I Major Histocompatibility Molecules by a Modified Pseudomonas Exotoxin," <u>Proc. Natl. Acad. Sci. USA</u> , 90:3530-4.
	C314 Donnelly <i>et al.</i> , (1997), "DNA Vaccines," <u>Annu. Rev. Immunol.</u> , 15:617-48.
	C315 Dube <i>et al.</i> , (1988), "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," <u>J. Biol. Chem.</u> , 263:17516-21.
	C316 Ellison <i>et al.</i> , (1982), "The Nucleotide Sequence of a Human Immunoglobulin C Gamma 1 Gene," <u>Nucleic Acids Res.</u> , 10:4071-9.
	C317 Faas <i>et al.</i> , (1993), "Phenotypically Diverse Mouse Thymic Stromal Cell Lines which Induce Proliferation and Differentiation Of Hematopoietic Cells," <u>Eur. J. Immunol.</u> , 23:1201-14.
	C318 Farmer <i>et al.</i> , (1995), "Distinction Between Gamma C Detection and Function in YT Lymphoid Cells and in the Granulocyte-Macrophage Colony-Stimulating Factor-Responsive Human Myeloid Cell Line, TF-1," <u>Blood</u> , 86:4568-78.
	C319 Fawell <i>et al.</i> , (1994), "Tat-Mediated Delivery of Heterologous Proteins into Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 91:664-8.
	C320 Fu <i>et al.</i> , (1993), "The Sheep Erythropoietin Gene: Molecular Cloning and Effect of Hemorrhage on Plasma Erythropoietin and Renal/Liver Messenger RNA in Adult Sheep," <u>Mol. Cell. Endocrinol.</u> , 93:107-16.
	C321 Gainsford <i>et al.</i> , (1996), "Leptin Can Induce Proliferation, Differentiation, and Functional Activation of Hemopoietic Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 93:14564-14568.
	C322 Gammon <i>et al.</i> , (1992), "Endogenous Loading of HLA-A2 Molecules with an Analog of the Influenza Virus Matrix Protein-Derived Peptide and Its Inhibition By An Exogenous Peptide Antagonist," <u>J. Immunol.</u> , 148:7-12.
	C323 Ghetie <i>et al.</i> , (1990), "Disseminated or Localized Growth of a Human B-Cell Tumor (Daudi) in SCID Mice," <u>Intl. J. Cancer</u> , 45:481.
	C324 Ghetie <i>et al.</i> , (1997), "FcRn: The MHC Class I-Related Receptor that is More Than an IgG Transporter," <u>Immunology Today</u> , 18(12):592-598.
	C325 Gillies <i>et al.</i> , (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-Ganglioside GD2 Antibody," <u>Hybridomas</u> , 10(3):347-56.
	C326 Goldwasser <i>et al.</i> , (1971), "Purification of Erythropoietin," <u>Proc. Natl. Acad. Sci. USA</u> , 68:697-8.
	C327 Goldwasser <i>et al.</i> , (1975), "Erythropoietin: Assay and Study of its Mode of Action," <u>Methods Enzymol.</u> , 37(Ptb):109-21.
<i>✓</i>	C328 Halin <i>et al.</i> , (2002), "Enhancement of the Antitumor Activity of Interleukin-12 by Targeted Delivery to Neovasculature," <u>Nature Biotechnology</u> , 20:264-269.

EXAMINER *David A. Saunders*

DATE CONSIDERED

*7/5/05*



















FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 09/780,668	CONF. NO.: 8264
		FILING DATE: February 9, 2001	GROUP: 1644
OTHER ART, JOURNAL ARTICLES ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C329	Handgretinger <i>et al.</i> , (2001), "Immunological Aspects of Haploidentical Stem Cell Transplantation in Children," <u>Ann. NY Acad. Sci.</u> , 938:340-57.	
	C330	Hashimoto <i>et al.</i> , (1999), "Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, Respectively," <u>J. Immunol.</u> , 163:583-9.	
	C331	Henikoff <i>et al.</i> , (1992), "Amino Acid Substitution Matrices from Protein Blocks," <u>Proc. Natl. Acad. Sci. USA</u> , 89:10915-10919.	
	C332	Hilgers <i>et al.</i> , (1999), "Sulfolipo-Cyclodextrin in Squalane-In-Water as a Novel and Safe Vaccine Adjuvant," <u>Vaccine</u> , 17:219-28.	
	C333	Holden <i>et al.</i> , (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675 (XP-002195344).	
	C334	Hori <i>et al.</i> , (1987), "Establishment of an Interleukin 2-Dependent Human T Cell Line from a Patient with T Cell Chronic Lymphocytic Leukemia Who is Not Infected with Human T Cell Leukemia/Lymphoma Virus," <u>Blood</u> , 70:1069-72.	
	C335	Hulet <i>et al.</i> , (1994), "Molecular Basis of Fc Receptor-Function," <u>Adv. Immunol.</u> , 57:1127.	
	C336	Huston <i>et al.</i> , (1988), "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced In <i>Escherichia Coli</i> ," <u>Proc. Natl. Acad. Sci. USA</u> , 85:5879.	
	C337	Isaacs <i>et al.</i> , (1998), "Therapy with Monoclonal Antibodies. II. The Contribution of Fc $\gamma$ Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function," <u>J. Immunol.</u> , 161:3862-3869.	
	C338	Jacobs <i>et al.</i> , (1985), "Isolation and Characterization of Genomic And cDNA Clones of Human Erythropoietin," <u>Nature</u> , 313:806-10.	
	C339	Jefferis <i>et al.</i> , (1990), "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors huFc $\gamma$ R," <u>Mol. Immunol.</u> , 27(12):1237-1240.	
	C340	Karlin <i>et al.</i> , (1990), "Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes," <u>Proc. Natl. Acad. Sci. USA</u> , 87:2264-8.	
	C341	Karlin <i>et al.</i> , (1993), "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," <u>Proc. Natl. Acad. Sci. USA</u> , 90:5873-7.	
	C342	Karpusas <i>et al.</i> , (1997), "The Crystal Structure of Human Interferon $\beta$ at 2.2-A Resolution," <u>Proc. Natl. Acad. Sci. USA</u> , 94:11813-11818.	
	C343	Kelner <i>et al.</i> , (1994), "Lymphotoxin: A Cytokine that Represents a New Class of Chemokine," <u>Science</u> , 266:1395-9.	

EXAMINER

David A. Saunders


DATE CONSIDERED

7/6/05

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 09/780,668	CONF. NO.: 8264
		FILING DATE: February 9, 2001	GROUP: 1644
OTHER ART, JOURNAL ARTICLES ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C344	Kirkman <i>et al.</i> , (1989), "Prolongation of Cardiac Allograft Survival in Murine Recipients Treated with a Diphtheria Toxin-Related Interleukin-2 Fusion Protein," <u>Transplantation</u> , 47(2):327-330.	
	C345	Klinman <i>et al.</i> , (1997), "Contribution of CPG Motifs to the Immunogenicity of DNA Vaccines," <u>J. Immunol.</u> , 158:3635-9.	
	C346	Kuntz <i>et al.</i> , (1982), "A Geometric Approach to Macromolecule-Ligand Interactions," <u>J. Mol. Biol.</u> , 161:269-88.	
	C347	Kurtz, (1982), "A New Candidate for the Regulation of Erythropoiesis. Insulin-Like Growth Factor I," <u>FEBS Lett.</u> , 149(1):105-8.	
	C348	Lai <i>et al.</i> , (1986), "Structural Characterization of Human Erythropoietin," <u>J. Biol. Chem.</u> , 261:3116-21.	
	C349	Lai <i>et al.</i> , (1998), "DNA Vaccines," <u>Crit. Rev. Immunol.</u> , 18:449-84.	
	C350	Lanza <i>et al.</i> , (1993), "Active Immunity against the CD4 Receptor by Using an Antibody Antigenized with Residues 41-55 of the First Extracellular Domain," <u>Proc. Natl. Acad. Sci. USA</u> , 90:11683-7.	
	C351	Lawn <i>et al.</i> , (1981), "DNA Sequence of a Major Human Leukocyte Interferon Gene," <u>Proc. Natl. Acad. Sci. USA</u> , 78:5435-9.	
	C352	Lin <i>et al.</i> , (1985), "Cloning and Expression of the Human Erythropoietin Gene," <u>Proc. Natl. Acad. Sci. USA</u> , 82:7580-4.	
	C353	Lin <i>et al.</i> , (1986), "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene," <u>Gene</u> , 44:201-9.	
	C354	Lode <i>et al.</i> , (1998), "Gene Therapy with a Single Chain Interleukin 12 Fusion Protein Induces T Cell-Dependent Protective Immunity in a Syngeneic Model of Murine Neuroblastoma," <u>Proc. Natl. Acad. Sci. USA</u> , 95:2475-80.	
	C355	Lorenz <i>et al.</i> , (1999), "Induction of Anti-Tumor Immunity Elicited by Tumor Cells Expressing a Murine LFA-3 Analog Via a Recombinant Vaccinia Virus," <u>Hum. Gene Ther.</u> , 10:623-31.	
	C356	Lotze <i>et al.</i> , (1996), "Cytokine Gene Therapy of Cancer Using Interleukin-12: Murine and Clinical Trials," <u>Ann. NY Acad. Sci.</u> , 795:440-54.	
	C357	Macdougall <i>et al.</i> , (1999), "Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients," <u>J. Am. Soc. Nephrol.</u> , 10:2392-5.	
	C358	MacLean <i>et al.</i> , (1996), "Enhancing the Effect of Theratope STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide," <u>J. Immunother.</u> , 19(4):309-316.	
	C359	Maghazachi <i>et al.</i> , (1997), "Interferon-Inducible Protein-10 and Lymphotoxin Induce the Chemotaxis and Mobilization of Intracellular Calcium in Natural Killer Cells through Pertussis Toxin-Sensitive and -Insensitive Heterotrimeric G-Proteins," <u>FASEB J.</u> , 11:765-74.	
EXAMINER			DATE CONSIDERED 7/5/05

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
<i>ms</i>	C360 Maloy <i>et al.</i> , (2001), "Regulatory T Cells in the Control of Immune Pathology," <u>Nature Immunol.</u> , 2:816-22.
	C361 Mariani <i>et al.</i> , (1997), "Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants," <u>Cancer</u> , 80:2378-84.
	C362 Marshall <i>et al.</i> , (1995), "Prediction of Peptide Affinity to HLA-DR Molecules," <u>Biomed. Pept. Proteins Nucleic Acids</u> , 1(3):157-62.
	C363 Marshall, K.W., (1994), "Role of the Polymorphic Residues in HLA-DR Molecules in Allele-Specific Binding of Peptide Ligands," <u>J. Immunol.</u> , 152:4946-57.
	C364 Martin <i>et al.</i> , (2001), "Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding," <u>Mol. Cell.</u> , 7(4):867-77.
	C365 McDonald, (1986), "Cloning, Sequencing, and Evolutionary Analysis of the Mouse Erythropoietin Gene," <u>Mol. Cell. Biol.</u> , 6:842-8.
	C366 McGonigle <i>et al.</i> , (1984), "Erythropoietin Deficiency and Inhibition of Erythropoiesis in Renal Insufficiency," <u>Kidney Int.</u> , 25(2):437-44.
	C367 McMahan <i>et al.</i> , (1991), "A Novel IL-1 Receptor, Cloned From B-Cells by Mammalian Expression is Expressed in Many Cell Types," <u>EMBO J.</u> , 10:2821-32.
	C368 McMahon <i>et al.</i> , (1990), "Pharmacokinetics and Effects of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Injections in Healthy Volunteers," <u>Blood</u> , 76:1718-22
	C369 Mehrotra <i>et al.</i> , (1993), "Effects of IL-12 on the Generation of Cytotoxic Activity in Human CD8+ T Lymphocytes," <u>J. Immunol.</u> , 151:2444-52.
	C370 Menard <i>et al.</i> , (1983), "Generation of Monoclonal Antibodies Reacting with Normal and Cancer Cells of Human Breast," <u>Cancer Res.</u> , 43:1295-300.
	C371 Miyake <i>et al.</i> , (1977), "Purification of Human Erythropoietin," <u>J. Biol. Chem.</u> , 252:5558-64.
	C372 Morrison <i>et al.</i> , (1984), "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-5.
	C373 Nagao <i>et al.</i> , (1992), "Nucleotide Sequence of Rat Erythropoietin," <u>Biochim. Biophys. Acta</u> , 1171(1):99-102.
	C374 Nastala <i>et al.</i> , (1994), "Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN-Gamma Production," <u>J. Immunol.</u> , 153:1697-706.
	C375 Naughton <i>et al.</i> , (1983), "Evidence for an Erythropoietin-Stimulating Factor in Patients with Renal and Hepatic Disease," <u>Acta Haematol.</u> , 69:171-9.
✓	C376 <del>Noguchi <i>et al.</i>, (1994), "A Mouse Mutant P53 Product Recognized by CD4+ and CD8+ T Cells," <u>Proc. Natl. Acad. Sci. USA</u>, 91:3171-5.</del> Neal <i>et al.</i> , (2004), <u>clin. Cancer Res.</u> , 10, 4839-47.

EXAMINER


*David A. Saunders*

DATE CONSIDERED

*7/5/05*

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
gal	C377 Orlandi <i>et al.</i> , (1989), "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," <u>Proc. Natl. Acad. Sci. USA</u> , 86:3833-7.
1	C378 Palmer <i>et al.</i> , (2001), "Phase I Study of the BLP 25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non-Small-Cell Lung Cancer," <u>Clinical Lung Cancer</u> , 3(1):49-57.
	C379 Palucka <i>et al.</i> , (1998), "Dendritic Cells as the Terminal Stage of Monocyte Differentiation," <u>J. Immunol.</u> , 160:4587-95.
	C380 Panina-Bordignon <i>et al.</i> , (1989), "Universally Immunogenic T Cell Epitopes: Promiscuous Binding to Human MHC Class II and Promiscuous Recognition by T Cells," <u>Eur. J. Immunol.</u> , 19:2237-42
	C381 Pavlovic-Kentera <i>et al.</i> , (1980), "Effects of Prostaglandin Synthetase Inhibitors, Salt Overload and Renomedullary Dissection on the Hypoxia Stimulated Erythropoietin Production in Rats," <u>Expt. Hematol.</u> , 8(Supp. 8):283-92.
	C382 Pedley <i>et al.</i> (1999), "Enhancement of Antibody-Directed Enzyme Prodrug Therapy in Colorectal Xenografts by an Antivascular Agent," <u>Cancer Res.</u> , 59:3998-4003.
	C383 Perussia <i>et al.</i> , (1992), "Natural Killer (NK) Cell Stimulatory Factor or IL-12 Has Differential Effects on the Proliferation of TCR-Alpha Beta+, TCR-Gamma Delta+ T Lymphocytes, and NK Cells," <u>J. Immunol.</u> , 149:3495-502.
	C384 Pluschke <i>et al.</i> , (1996), "Molecular Cloning of a Human Melanoma-Associated Chondroitin Sulfate Proteoglycan," <u>Proc. Natl. Acad. Sci. USA</u> , 93:9710-5.
	C385 Poon <i>et al.</i> , (1995), "Structure and Function of Several Anti-Dansyl Chimeric Antibodies Formed by Domain Interchanges Between Human IgM and Mouse IgG2b," <u>J. Biol. Chem.</u> , 270:8571-7.
	C386 Queen <i>et al.</i> , (1989), "A Humanized Antibody that Binds to the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 86:10029-33.
	C387 Radhakrishnan <i>et al.</i> , (1996), "Zinc Mediated Dimer of Human Interferon-Alpha 2b Revealed by X-Ray Crystallography," <u>Structure</u> 4:1453-63.
	C388 Ramachandran <i>et al.</i> , (1968) "Conformation of Polypeptides and Proteins," <u>Adv. Prot. Chem.</u> , 23:283-438. (1968) (At Pgs. 285-94).
	C389 Rarey <i>et al.</i> , (1995), "Time-Efficient Docking of Flexible Ligands into Active Sites Of Proteins," <u>Proc. Int. Conf. Intell. Syst. Mol. Biol.</u> 3:300-8.
	C390 Resegotti <i>et al.</i> , (1981), "Treatment of Aplastic Anaemia with Methenolone, Stanozolol and Nandrolone. A Report of 130 Cases," <u>Panminerva Med.</u> , 23:243-8.
	C391 Riechmann <i>et al.</i> , (1988), "Reshaping Human Antibodies for Therapy," <u>Nature</u> , 332:323-7.
✓	C392 Robinson <i>et al.</i> , (1998), "Optimizing the Stability of Single-Chain Proteins by Linker Length and Composition Mutagenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 95:5929-34.

EXAMINER


David A. Spencer

DATE CONSIDERED

7/5/05

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
<i>g</i>	C393 Rothmann et al., (1982), "Erythropoietin-Dependent Erythrocytosis associated with Hepatic Angiosarcoma," <u>J. Surg. Oncol.</u> , 20:105-8.
	C394 Runkel et al., (1998), "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon-B (IFN-B)," <u>Pharmaceutical Res.</u> , 15:641-649.
	C395 Sakano et al., (1980), "Two Types of Somatic Recombination are Necessary for the Generation of Complete Immunoglobulin Heavy-Chain Genes," <u>Nature</u> , 286:676-683.
	C396 Sali et al., (1993), "Comparative Protein Modelling by Satisfaction of Spatial Restraints," <u>J. Mol. Biol.</u> , 234:779-815.
	C397 Schechter et al., (1997), "Tissue Factor is Induced by Monocyte Chemoattractant Protein-1 in Human Aortic Smooth Muscle And THP-1 Cells," <u>J. Biol. Chem.</u> , 272:28568-73.
	C398 Senior et al., (2000), "Cleavage of a Recombinant Human Immunoglobulin A2 (IgA2)-IgA1 Hybrid Antibody by Certain Bacterial IgA1 Proteases," <u>Infect. Immun.</u> , 68(2):463-9.
	C399 Sharp et al., (1988), "Codon Usage Patterns in <i>Escherichia coli</i> , <i>Bacillus subtilis</i> , <i>Saccharomyces cerevisiae</i> , <i>Schizosaccharomyces pombe</i> , <i>Drosophila melanogaster</i> and <i>Homo sapiens</i> ; a Review of the Considerable Within-Species Diversity," <u>Nucleic Acids Res.</u> , 16(17):8207-8211.
	C400 Simonsen et al., (1983), "Isolation and Expression of an Altered Mouse Dihydrofolate Reductase cDNA," <u>Proc. Natl. Acad. Sci. USA</u> , 80:2495-2499.
	C401 Smith et al., (1981), "Identification of Common Molecular Subsequences," <u>J. Mol. Biol.</u> , 147:195-197.
	C402 Soligo et al., (1998), "Expansion of Dendritic Cells Derived from Human CD34+ Cells in Static And Continuous Perfusion Cultures," <u>Br. J. Haematol.</u> , 101:352-63.
	C403 Spivak et al., (1989), "The In Vivo Metabolism of Recombinant Human Erythropoietin in The Rat," <u>Blood</u> , 73:90-9.
	C404 Sturniolo et al., (1999), "Generation of Tissue-Specific and Promiscuous HLA Ligand Databases Using DNA Microarrays and Virtual HLA Class II Matrices," <u>Nat. Biotech.</u> , 17(6):555-61.
	C405 Suliman et al., (1996), "Cloning of a cDNA Encoding Bovine Erythropoietin and Analysis of Its Transcription in Selected Tissues," <u>Gene</u> , 171:275-80.
	C406 Takahashi et al. (2000), "Immunologic Self-Tolerance Maintained by CD25+ CD4+ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-Associated Antigen," <u>J. Exp. Med.</u> , 192(2):303-309.
	C407 Takai, (2002), "Roles of Fc Receptors in Autoimmunity," <u>Nat. Rev. Immunol.</u> , 2(8):580-92.
	C408 Taniguchi et al., (1980), "Expression of the Human Fibroblast Interferon Gene in <i>Escherichia Coli</i> ," <u>Proc. Natl. Acad. Sci. USA</u> , 77:5230-5233.

EXAMINER


*David A. Saunders*

DATE CONSIDERED

*7/5/05*

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO.: LEX-011

APPLICANT(S): Gillies et al.

SERIAL NO.: 09/780,668

CONF. NO.: 8264

FILING DATE: February 9, 2001

GROUP: 1644

## OTHER ART, JOURNAL ARTICLES ETC.

EXAM.  
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

✓	C409	Thurner, (1999), "Generation of Large Numbers of Fully Mature and Stable Dendritic Cells from Leukapheresis Products for Clinical Application," <u>J. Immunol. Methods</u> , 223:1-15.
	C410	Tiruppathi <i>et al.</i> , (1996), "Isolation and Characterization of a Cell Surface Albumin-Binding Protein from Vascular Endothelial Cells," <u>Proc. Nat. Acad. Sci. USA</u> , 93:250-4.
	C411	Van Den Eynde <i>et al.</i> , (1989), "Presence on a Human Melanoma of Multiple Antigens Recognized By Autologous CTL," <u>Int. J. Cancer</u> , 44:634-40.
	C412	Van Der Bruggen <i>et al.</i> , (1991), "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," <u>Science</u> , 254:1643-7.
	C413	Van Heyningen <i>et al.</i> , (1982), "Human MHC Class II Molecules as Differentiation Markers," <u>Immunogenetics</u> , 16:459-69.
	C414	Voest <i>et al.</i> , (1995), "Inhibition of Angiogenesis in Vivo by Interleukin 12," <u>J. Natl. Canc. Inst.</u> , 87:581-6.
	C415	Von Heijne <i>et al.</i> , (1986), "A New Method for Predicting Signal Sequence Cleavage Sites," <u>Nucleic Acid Res.</u> , 14:4683-4690.
	C416	Ward <i>et al.</i> , (1995), "The Effector Functions of Immunoglobulins: Implications for Therapy," <u>Therapeutic Immunology</u> , 2:77-94.
	C417	Watson <i>et al.</i> , (1984), "Compilation of Published Signal Sequences," <u>Nucleic Acid Res.</u> , 12:5145-5164.
	C418	Weitkamp <i>et al.</i> , (1973), "Additional Data on the Population Distribution of Human Serum Albumin Genes; Three New Variants," <u>Ann. Hum. Genet.</u> , 37:219-26.
	C419	Wetzel <i>et al.</i> , (2001), "BAY50-4798, an Interleukin-2 (IL <sub>2</sub> ) Variant, demonstrates Selective Activation of Human and Chimpanzee T Cells Relative to NK Cells but Shows Less Selectivity for T Cells from Monkeys and Rodents," <u>ASCO Annual Meeting</u> , Abstract 1051..
	C420	Woof <i>et al.</i> , (1986), "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G," <u>Mol. Immunol.</u> , 23:319-30.
	C421	Wu <i>et al.</i> , (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.
	C422	Wyatt <i>et al.</i> , (1998), "The Antigenic Structure of the HIV Gp120 Envelope Glycoprotein," <u>Nature</u> , 393:705-11.
	C423	Wysocka <i>et al.</i> , (1995), "Interleukin-12 is Required for Interferon-Gamma Production and Lethality in Lipopolysaccharide-Induced Shock in Mice," <u>Eur. J. Immunol.</u> , 25:672-6.
	C424	Yan <i>et al.</i> , (1996), "Characterization of an Ig VH Idiotope that Results in Specific Homophilic Binding and Increased Avidity for Antigen," <u>J. Immunol.</u> , 157:1582-8.
✓	C425	Yeh <i>et al.</i> , (1992), "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," <u>Proc. Natl. Acad. Sci. USA</u> , 89:1904-8.







EXAMINER

David A. Summers

DATE CONSIDERED

7/06/05



FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-011	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 09/780,668	CONF. NO.: 8264
		FILING DATE: February 9, 2001	GROUP: 1644
OTHER ART, JOURNAL ARTICLES ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C426	Zhang <i>et al.</i> , (1994), "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis. Identification of a Mutated Protein that Inhibits MCP-1-Mediated Monocyte Chemotaxis," <u>J. Biol. Chem.</u> , 269:15918-24.	
	C427	Zhu <i>et al.</i> , (2001), "MHC Class I-Related Neonatal Fc Receptor for IgG is Functionally Expressed in Monocytes, Intestinal Macrophages and Dendritic Cells," <u>J. Immunol.</u> , 166:3266-3276.	
	C428	Zuckier <i>et al.</i> , (1998), "Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to In Vivo Half-Life," <u>Cancer Res.</u> , 58(17):3905-8.	
EXAMINER			DATE CONSIDERED 

3166771

EXAMINER	DATE CONSIDERED
----------	-----------------